Relationships between Ki-67 labelling index, amplification of the epidermal growth factor receptor gene, and prognosis in human glioblastomas

The aim of this study was to determine possible relationships between Ki-67 labelling index (Ki-67 LI), amplification of the epidermal growth factor receptor (EGFR) gene, and prognosis in human glioblastomas. Ki-67 LI was determined on cryosections of biopsy specimens of 20 human glioblastomas with...

Full description

Saved in:
Bibliographic Details
Published in:Acta neurochirurgica 1992-01, Vol.117 (3-4), p.182-186
Main Authors: TORP, S. H, HELSETH, E, DALEN, A, UNSGAARD, G
Format: Article
Language:English
Subjects:
Actuarial Analysis
Adult
Aged
Biological and medical sciences
Brain Neoplasms - genetics
Brain Neoplasms - mortality
Brain Neoplasms - pathology
Brain Neoplasms - surgery
Cell Division - genetics
Cell Division - physiology
ErbB Receptors - genetics
Female
Gene Amplification - genetics
Gene Expression Regulation, Neoplastic - physiology
Glioma - genetics
Glioma - mortality
Glioma - pathology
Glioma - surgery
Humans
Ki-67 Antigen
Male
Medical sciences
Middle Aged
Mitotic Index
Neurology
Nuclear Proteins - genetics
Prognosis
Survival Analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to determine possible relationships between Ki-67 labelling index (Ki-67 LI), amplification of the epidermal growth factor receptor (EGFR) gene, and prognosis in human glioblastomas. Ki-67 LI was determined on cryosections of biopsy specimens of 20 human glioblastomas with a mouse anti-human Ki-67 monoclonal antibody. Amplification of the EGFR gene was determined by slot blot and Southern blot analyses of DNA extracted from the tumour biopsies. The Ki-67 LI was higher in the glioblastoma group with EGFR gene amplification (8 tumours, median value of Ki-67 LI 4.2, range 0.4-24.6) than in those without EGFR gene amplification (12 tumours, median value of Ki-67 LI 0.8, range 0.2-11.8) (0.05 p less than 0.1). The glioblastoma patients with Ki-67 LI greater than 1.5 (10 tumours) had a statistically significant shorter survival than those with Ki-67 LI less than 1.5 (10 tumours) (p less than 0.05). The glioblastoma patients with EGFR gene amplification lived shorter time than those without EGFR gene amplification (p greater than 0.05).
ISSN:0001-6268
0942-0940
DOI:10.1007/BF01400618